Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Aug 5;34(8):1119-1125.
doi: 10.1136/ijgc-2024-005401.

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

Robert L Coleman  1 , Domenica Lorusso  2 , Ana Oaknin  3 , Sabrina Chiara Cecere  4 , Hannelore Denys  5 , Nicoletta Colombo  6   7 , Toon van Gorp  8 , Jason A Konner  9 , Margarita Romeo Marin  10 , Philipp Harter  11 , Conleth Murphy  12 , Yuemei Wang  13 , Brooke Esteves  13 , Michael Method  13 , Ursula Matulonis  14
Affiliations
Clinical Trial

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

Robert L Coleman et al. Int J Gynecol Cancer. .

Abstract

Objective: The single-arm, phase II SORAYA trial (NCT04296890) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer (n=105 (efficacy-evaluable)) met its primary endpoint with an objective response rate of 32.4% (95% CI, 23.6 to 42.2). Here we report final SORAYA trial results for overall survival and post hoc objective response rates in subgroups by sequence and number of prior therapies.

Methods: Eligible patients had high-grade serous platinum-resistant ovarian cancer with high FRα expression and one to three prior therapies (prior bevacizumab required). Enrolled participants received 6 mg/kg mirvetuximab soravtansine-gynx adjusted ideal body weight intravenously once every 3 weeks until progressive disease, unacceptable toxicity, withdrawal of consent, or death. Final overall survival and post hoc objective response rates were assessed in efficacy-evaluable participants. The safety population included all patients who received ≥1 dose of mirvetuximab soravtansine-gynx.

Results: At data cut-off (December 22, 2022; n=105), final median overall survival was 15.0 months (95% CI, 11.5 to 18.7). Median overall survival in participants with one to two prior therapy lines was 18.7 months (95% CI, 13.8 to not estimable (NE)) and 11.6 months (95% CI, 7.1 to 16.7) with three prior therapy lines. Median overall survival was 15.0 months (95% CI, 11.5 to NE) in participants with prior poly (ADP-ribose) polymerase inhibitor (PARPi) treatment versus 14.0 months (95% CI, 7.1 to NE) in those without. Objective response rate (data cut-off: November 17, 2021) differed among participants who received mirvetuximab soravtansine-gynx as their first treatment in the platinum-resistant setting (34.8%; 95% CI, 23.5 to 47.6) versus a different first treatment (28.2%; 95% CI, 15.0 to 44.9) or had received prior bevacizumab in a platinum-sensitive (34.0%; 95% CI, 24.6 to 44.5) versus platinum-resistant setting (17.6%; 95% CI, 3.8 to 43.4). No new safety signals were observed.

Conclusion: These results support the clinically meaningful efficacy of mirvetuximab soravtansine-gynx in FRα-expressing platinum-resistant ovarian cancer, irrespective of prior treatment or sequence.

Keywords: Ovarian Cancer; Ovarian Neoplasms.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RLC: Research funding and consulting or advisory fees: AstraZeneca/MedImmune, Clovis Oncology. Consulting and advisory fees: Genentech/Roche, Genmab, Tesaro, OncoMed, Sotio, Oncolytics, AbbVie/Stemcentrx, ImmunoGen, AbbVie, Agenus, Novocure, Merck, OncXerna Therapeutics, Alkermes, Gradalis, Regeneron. Research funding: AstraZeneca, Merck, Roche/Genentech, Abbott/AbbVie, ImmunoGen. DL: Research funding and consulting or advisory fees: PharmaMar, Clovis Oncology, GSK, MSD, AstraZeneca, Amgen, Seagen/Genmab, Sutro, ImmunoGen, Merck Serono. Research funding: Clovis, Incyte, Novartis, Roche, Concept. AO: Research funding and consulting or advisory fees: Clovis Oncology, Eisai Limited, F. Hoffmann-La Roche. Consulting or advisory fees: Roche, AstraZeneca, PharmaMar, Tesaro, ImmunoGen, Genmab, Mersana Therapeutic, GSK, Deciphera Pharmaceutical, AGENUS, Corcept Therapeutics, Eisai, EMD Serono, Got It Consulting, KL Logistics, Medison Pharma, Merck Sharp & Dohme, Novocure, prIME Oncology, Sattucklabs, Sutro Biopharma, iTheos. Research funding: AbbVie Deutschland, Ability Pharmaceuticals, Advaxis Inc., Aeterna Zentaris, AMGEM, SA, Aprea Therapeutics, AB, Regeneron Pharmaceuticals. SCC: Research funding and consulting or advisory fees: Roche, Pfizer. Consulting or advisory fees: PharmaMar, Tesaro, Clovis Oncology. Research funding: AstraZeneca, MSD. HD: Consulting or advisory fees: Pfizer, Roche, PharmaMar, AstraZeneca, Eli Lilly and Company, Novartis, Amgen, GSK, MSD, Seagen, and Gilead. Travel, accommodations, expenses: Pfizer, Roche, PharmaMar, Teva, AstraZeneca, MSD, GSK and Gilead. Research grant: Gilead. All payments institutional. NC: Consulting or advisory fees: Roche/Genentech, AstraZeneca, Clovis Oncology, Pfizer, MSD Oncology, Tesaro, GSK, ImmunoGen, Pfizer, Mersana, Eisai, Advaxis. TvG: Consulting or advisory fees: AstraZeneca, BioNTech SE, Eisai, GSK, ImmunoGen, Incyte, MSD/Merck, OncXerna Therapeutics, Seagen, and Tubulis. Travel, accommodations, and/or expenses: AstraZeneca, GSK, ImmunoGen, MSD/Merck, and PharmaMar. Research funding: Amgen, Roche, and AstraZeneca. All payments institutional. JAK: Consulting or advisory fees: AstraZeneca, Clovis Oncology. Research funding: ImmunoGen. MRM: Consulting or advisory fees: Tesaro/Glaxo, AstraZeneca, Roche, Eisai, Pfizer. PH: Honoraria: Amgen, AstraZeneca, GSK, Roche, Sotio, Stryker, Zai Lab, MSD, Clovis, Eisai, Mersana, Exscientia. Advisory Board: AstraZeneca, Roche, GSK, Clovis, ImmunoGen, MSD, Miltenyi, Novartis, Eisai. Institutional research funding: AstraZeneca, Roche, GSK, Genmab, DFG, European Union, DKH, ImmunoGen, Seagen, Clovis Oncology, Novartis. CM: Honoraria: Janssen Pharmaceuticals. Travel, accommodations, and/or expenses: Pfizer, Inc., Bayer AG. YW: ImmunoGen employee. BE: ImmunoGen employee. MM: ImmunoGen employee. UM: Consulting or advisory fees: NextCure, Allarity, Ovarian Cancer Research Alliance, Pfizer, Profound Bio, Eisai, CureLab, ImmunoGen, Trillium, Agenus, Novartis, Boehringer Ingelheim. Participation in a Data Safety Monitoring Board: Alkermes, Symphogen. Speakers Bureau: Med Learning Group.

Figures

Figure 1
Figure 1
Final overall survival and post hoc subgroup analyses by sequence and number of prior therapies. Shown are Kaplan–Meier plots (data cut-off: December 22, 2022) of final overall survival in (A) the efficacy-evaluable population and (B) in participants who had one to two prior lines of therapy (blue) versus three prior lines of therapy (red). (C) Shows objective response rate (data cut-off: November 17, 2021) in the overall population and post hoc analysis results for objective response rate in participants who received mirvetuximab soravtansine-gynx as their first treatment in the platinum-resistant setting versus a different first treatment in the platinum-resistant setting and in participants who were first exposed to bevacizumab in the platinum-sensitive versus platinum-resistant setting. aOne patient in the efficacy-evaluable population had four prior lines of therapy. bOf the 17 participants who received bevacizumab in the platinum-resistant setting (16% of all participants), 8 (47%) had stage IV disease at diagnosis and 10 (59%) received mirvetuximab soravtansine-gynx as fourth-line therapy. Six participants (6% of all participants) received bevacizumab in both the platinum-sensitive and platinum-resistant settings.
See this image and copyright information in PMC

References

    1. Richardson DL, Eskander RN, O’Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol 2023;9:851–9. 10.1001/jamaoncol.2023.0197 - DOI - PubMed
    1. Ab O, Whiteman KR, Bartle LM, et al. . IMGN853, a folate receptor-Α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther 2015;14:1605–13. 10.1158/1535-7163.MCT-14-1095 - DOI - PubMed
    1. Matulonis UA, Lorusso D, Oaknin A, et al. . Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol 2023;41:2436–45. 10.1200/JCO.22.01900 - DOI - PMC - PubMed
    1. U.S. Food & Drug Administration . BLA accelerated approval. Available: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761310Orig... [Accessed 21 Feb 2023].
    1. ELAHERE (mirvetuximab soravtansine-gynx) [prescribing information]. Waltham, MA: ImmunoGen, Inc.; 2022.

Publication types

MeSH terms

Associated data